UNSPSC 51184011: Glisolamide

This classification denotes an anti-diabetic agent with the molecular formula C20H26N4O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F83U6T74XR, chemically known as 3-isozazolecarboxamide, n-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl- but more generally known as glisolamide, which bears US NIH Compound Identifier 65713. European Medicines Agency schedules Glisolamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07932MIG.

UNSPSC 51184011 Glisolamide is a Commodity code that captures generic and branded pharmaceutical products supplied through multi-source cooperative purchasing agreements to state and local government healthcare facilities. The scope of work under this code encompasses the manufacturing and wholesale supply of pharmaceuticals—both branded and generic formulations—distributed through authorized pharmaceutical wholesalers to state agencies, county health departments, municipal clinics, and other public healthcare entities. Recent solicitations frame the work as comprehensive pharmaceutical procurement requiring manufacturers to supply products with verified National Drug Codes (NDCs), maintain cGMP and Drug Supply Chain Security Act compliance, establish relationships with authorized wholesalers, and offer flexible pricing models (flat price, net price formats, or WAC-minus structures). The issuing bodies for this code are primarily state procurement offices administering multistate cooperative purchasing vehicles, which leverage consolidated demand across multiple jurisdictions to negotiate volume pricing and streamline vendor management.

Geographic concentration in recent activity centers on the Upper Midwest and Pacific Northwest, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—administered by the Minnesota Department of Administration's Office of State Procurement—issuing a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products spanning participating state and local government facilities in Minnesota and Oregon. The MMCAP RFP, due March 26, 2026, requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with evaluation weighted heavily on price competitiveness (75 percent) and administrative compliance (20 percent combined), and contract terms of two years for new responders with optional extensions. The procurement imposes insurance requirements including $5 million commercial general liability and $2 million network security and privacy liability, compliance penalties of $200 to $1,500 per violation, and a 3 percent administrative fee on all purchases.